OVER the next five years the use
of biologic disease-modifying
antirheumatic drugs (DMARDs) in
the treatment of rheumatoid
arthritis is set to increase, according
to analysts at Datamonitor.
Based on a survey of
rheumatologists the research
suggests that by 2015 there will be
a 25% jump in patients with mild
rheumatoid arthritis using biologics,
up from 12% in 2010.
Datamonitor also estimated that
the number patients suffering
moderate rheumatoid arthritis
using biologics will rise from the
current 30% to 48% by 2015, and
that the number of severe patients
using biologics will rise to 68%.
In addition, the survey results
indicated that non-tumor necrosis
factor biologics incl. Orencia
(abatacept), Rituxan (rituximab)
and Actemra (tocilizumab) will also
“capture a substantial proportion of
first- and second-line patients
receiving biologics”.The above article was sent to subscribers in Pharmacy Daily's issue from 01 Oct 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Oct 10
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.